Dianthus Therapeutics (DNTH) Tops Q2 EPS by 77c

Dianthus Therapeutics (NASDAQ: DNTH) reported Q2 EPS of ($0.09), $0.77 better than the analyst estimate of ($0.86). Revenue for the quarter came in at $760 thousand versus the consensus estimate of $297.42 thousand.

For earnings history and earnings-related data on Dianthus Therapeutics (DNTH) click here.

You May Also Be Interested In

• Musalem: strong growth and investment influencing bond market - CNBC
• Deere conference call: 2027 orders up mid-single digits from last year)
• Arctos agrees to buy 10% of Atlanta Falcons at $10.6 billion valuation - Bloomberg